Genentech, OSI shares hit by lung-cancer study
October 6th, 2008
Shares of Genentech Inc. and OSI Pharmaceuticals fell Monday after the companies reported disappointing results from a study that tested Genentech’s top-selling oncology drug Avastin with OSI’s Tarceva in the treatment of advanced lung cancer.